Letter

Adjuvant trastuzumab for breast cancer: Advent of pharmacogenetics raises many issues

BMJ 2005; 331 doi: 10.1136/bmj.331.7526.1202-a (Published 17 November 2005)
Cite this as: BMJ 2005;331:1202.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Hazel Thornton (hazelcagct@keme.co.uk), honorary visiting fellow
  1. Department of Health Sciences, University of Leicester “Saionara,” Colchester CO5 7EA

    EDITOR—Kell and Power [previous letter] at last clarify for everyone that at least 20% of patients with positive immunochemical results will not benefit from trastuzumab.1 These are expensive false positives at £20 000 yearly per patient, both for the health system and for patients' quality of life—or, indeed, life at all, bearing in mind the death rate …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular